ArticleBrain sciences2025
Predictive Value of Hyperintense Acute Reperfusion Marker in Transient Ischemic Attacks: Stroke Recurrence and TOAST Classification.
Article in Brain sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTransient ischemic attack (TIA) is a recognized precursor of stroke that also indicates a high risk of recurrence. The Hyperintense Acute Reperfusion Marker (HARM), which is linked to blood-brain barrier disruption, may serve as a novel imaging biomarker for TIA.
methodsA retrospective cohort study of 715 patients with TIA evaluated the predictive value of HARM for stroke recurrence and its association with TOAST subtype. Imaging findings, including those of diffusion-weighted imaging, were analyzed using logistic regression.
resultsHARM-positive patients had significantly higher recurrence rates at 3 months (20.9%; odds ratio [OR] = 5.3) and 1 year (30.2%; OR = 5.8) compared to HARM-negative patients, relative to other imaging markers (
conclusionsHARM is a promising imaging biomarker for predicting stroke recurrence and etiology in patients experiencing TIA. Incorporating HARM into clinical frameworks may enhance diagnostic and prognostic accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.